Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

ABSTRACT:

Objectives

Platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In cohorts A-C of the multicohort phase 1/2 study KEYNOTE-021 (Clinicaltrials.gov, NCT02039674), we evaluated combinations of platinum-doublet chemotherapy with the anti-programmed death 1 monocloncal antibody pembrolizumab.

Materials and methods

Patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations were randomized to pembrolizumab 2 or 10 mg/kg Q3W plus carboplatin area under the serum concentration-time curve (AUC) 6 mg/mL/min plus paclitaxel 200 mg/m² (cohort A, any histology), carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m² plus bevacizumab 15 mg/kg (coho

SUBMITTER: Gadgeel SM 

PROVIDER: S-EPMC6886233 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature